Reportlinker Adds Novartis AG: PharmaVitae Profile

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Novartis AG: PharmaVitae Profile

http://www.reportlinker.com/p0133012/Novartis-AG-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Novartis's performance against key rivals in the prescription pharmaceutical sector

*Assess Novartis's strategy of diversification from the typical Big Pharma growth model, including its movement into the generics market via Sandoz

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company Introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2003-15 7

Novartis: PharmaVitae forecasts at a glance 8

Strategic insight 9

Novartis is forecast to deliver strongest organic growth within Big Pharma 2009-15 9

Diversified prescription pharma offering integral to sales growth performance 9

Exposure to generic competition will blunt branded pharmaceutical sales growth 10

Evolution of vaccine offering will drive steady revenue growth 12

Sandoz poised to exploit diverse segments of global generics market 13

Further diversification to be driven by Alcon acquisition 16

SWOT analysis 19

Strengths 19

Weaknesses 20

Opportunities 21

Threats 22

TABLE OF CONTENTS 23

Table of figures 25

Chapter 3 Quarterly update 26

Latest quarterly sales 26

Latest comment 27

Q2 2010 27

Novartis: blockbuster revenues beckon for multiple sclerosis pill 27

Lucentis shows potential in diabetic macular edema 27

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates 28

Q1 2010 30

Novartis: Debiopharm deal strengthens hepatitis C pipeline 30

Novartis: Fanapt marks weak return to competitive antipsychotics market 31

Novartis eyes Alcon merger 32

Q4 2009 32

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML 32

Q2 2009 34

Novartis: Afinitor boasts considerable commercial potential 34

Q1 2009 35

Novartis: Extavia launch provides foothold in MS market 35

Latest prescription pharma product news 36

Q2 2010 36

Q1 2010 37

Q4 2009 38

Q3 2009 40

Q2 2009 40

Q1 2009 41

Latest corporate news 42

Q2 2010 42

Q1 2010 42

Q4 2009 43

Q3 2009 44

Q2 2009 45

Q1 2009 45

Chapter 4 Company Introduction 46

Key findings 46

Background 47

Key corporate developments 47

M&A history 47

Push into generics market 48

Sandoz 48

Movement into vaccines/diagnostics 49

Chiron 49

Alcon deal demonstrates further diversification 50

One eye on Alcon: a strong fit with Novartis Ophthalmics 50

Recent M&A in branded prescription segment 51

Chapter 5 Company sales 52

Key findings 52

Prescription pharmaceutical sales and growth rate analysis, 2003-15 53

Product analysis 55

Product analysis, 2003-09 57

Product analysis, 2009-15 61

Product analysis, 2009-15 61

Therapy area analysis 65

Geographic analysis 68

Launch/core/expiry analysis 70

Explanation of launch/core/expiry analysis 70

Launch analysis, 2009-15 71

Core analysis, 2009-15 72

Expiry analysis, 2009-15 73

Generics analysis, 2009-15 74

Launch/core/expiry configuration, 2009-15 76

Molecule type analysis 77

Externalization analysis 80

Chapter 6 Company financials 83

Key findings 83

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 84

Operating costs and profit analysis 85

Operating costs and profit analysis, 2003-09 86

Operating cost ratio and profit margin analysis, 2003-09 87

Operating cost ratio and profit margin analysis, 2009-15 88

Operating costs and profit analysis, 2009-15 89

Chapter 7 Key products 90

Overview 90

Glivec/Gleevec 91

Summary 92

Sales forecast 93

Gilenia 95

Summary 96

Sales forecast 97

QMF149 98

Summary 99

Sales forecast 100

QVA149 101

Summary 102

Sales forecast 103

Tasigna 104

Summary 105

Sales forecast 106

Diovan/Co-Diovan 107

Summary 108

Sales forecast 109

Co-Diovan 110

Summary 110

Sales forecast 111

Zometa (includes Aclasta/Reclast) 112

Summary 113

Sales forecast 114

Femara 115

Summary 116

Sales forecast 117

Sandostatin 118

Summary 118

Sales forecast 119

Chapter 8 Appendix 120

References 120

Abbreviations 120

Exchange rates 121

About Datamonitor 122

About Datamonitor Healthcare 122

Datamonitor consulting 122

Disclaimer 124

List of Tables

Table 1: Novartis - PharmaVitae forecasts at a glance 8

Table 2: Novartis quarterly sales ($m), Q109-Q110 26

Table 3: Novartis product portfolio overview ($m), 2003-09 57

Table 4: Novartis product portfolio overview ($m), 2009-15 61

Table 5: Novartis prescription pharmaceutical sales by therapy area ($m), 2009-15 67

Table 6: Novartis prescription pharmaceutical sales by geographic region ($m), 2009-15 69

Table 7: Novartis launch portfolio overview ($m), 2009-15 71

Table 8: Novartis core portfolio overview ($m), 2009-15 72

Table 9: Novartis expiry portfolio overview ($m), 2009-15 73

Table 10: Novartis (Sandoz) generics portfolio overview ($m), 2009-15 74

Table 11: Novartis prescription pharmaceutical sales by molecule type ($m), 2009-15 79

Table 12: Novartis prescription pharmaceutical sales by source ($m), 2009-15 82

Table 13: Total Novartis sales by business unit ($m), 2003-09 84

Table 14: Novartis operating revenue/cost analysis ($m), 2003-09 86

Table 15: Novartis operating cost ratio analysis (% of total revenues), 2003-09 87

Table 16: Novartis operating cost ratio analysis (% of total revenues), 2009-15 88

Table 17: Novartis operating revenue/cost analysis ($m), 2009-15 89

Table 18: Novartis Key products overview 90

Table 19: Glivec/Gleevec: overview 92

Table 20: Glivec/Gleevec: sales forecast ($m), 2009-15 93

Table 21: Gilenia: overview 96

Table 22: Gilenia: sales forecast ($m), 2009-15 97

Table 23: QMF149: overview 99

Table 24: QMF149: sales forecast ($m), 2009-15 100

Table 25: QVA149: overview 102

Table 26: QVA149: sales forecast ($m), 2009-15 103

Table 27: Tasigna: overview 105

Table 28: Tasigna: sales forecast ($m), 2009-15 106

Table 29: Diovan: overview 108

Table 30: Diovan: sales forecast ($m), 2009-15 109

Table 31: Co-Diovan: overview 110

Table 32: Co-Diovan: sales forecast ($m), 2009-15 111

Table 33: Zometa: overview 113

Table 34: Zometa: sales forecast ($m), 2009-15 114

Table 35: Femara: overview 116

Table 36: Femara: sales forecast ($m), 2009-15 117

Table 37: Sandostatin: overview 118

Table 38: Sandostatin: sales forecast ($m), 2009-15 119

Table 39: Exchange rates, 2010 121

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Novartis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Novartis's financial performance ($m), 2003-15 7

Figure 4: Novartis prescription pharmaceutical sales growth by business area ($m), 2009-15 10

Figure 5: Novartis prescription pharmaceutical sales growth by business area (branded portfolio segmented) ($m), 2009-15 11

Figure 6: Sandoz corporate structure demonstrating diverse growth opportunities 13

Figure 7: Sandoz M&A driven geographic expansion ($m), 2003-15 14

Figure 8: Synergies between Alcon and Novartis 17

Figure 9: Novartis SWOT analysis 19

Figure 10: Sandoz M&A history, 2001-09 48

Figure 11: Novartis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 53

Figure 12: Novartis Key product sales ($m), 2003-15 55

Figure 13: Novartis key sales growth drivers and resistors ($m), 2003-09 58

Figure 14: Novartis key sales growth drivers and resistors ($m), 2009-15 63

Figure 15: Novartis prescription pharmaceutical sales by therapy area ($m), 2003-15 65

Figure 16: Novartis prescription pharmaceutical sales by geographic region ($m), 2003-15 68

Figure 17: Novartis launch/core/expiry configuration ($m), 2009-15 76

Figure 18: Novartis prescription pharmaceutical sales by molecule type ($m), 2003-15 78

Figure 19: Novartis prescription pharmaceutical sales by source ($m), 2003-15 81

Figure 20: Novartis operating revenue/cost analysis ($m), 2003-15 85

To order this report:

Healthcare Industry: Novartis AG: PharmaVitae Profile

Healthcare Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo